{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:13:46Z","timestamp":1793787226377,"version":"4.6.1"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"Importance<\/jats:title>Chemotherapy-induced peripheral neuropathy (CIPN) is a common, dose-limiting adverse effect of taxane-based chemotherapies. Currently, there is no established strategy for prevention or treatment.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare the effectiveness of 1-sided hand cooling and compression for preventing CIPN in patients with primary breast cancer receiving taxane-based chemotherapy.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>The POLAR randomized clinical trial was conducted at the National Center for Tumor Diseases Heidelberg between November 2019 and January 2022. Female patients with breast cancer who received weekly nab-paclitaxel\u2013based or paclitaxel-based neoadjuvant or adjuvant chemotherapy were enrolled. Patients with prior chemotherapy, preexisting neuropathy, or neuropathy-related comorbidities were excluded.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Patients were randomized 1:1 to cooling or compression of the dominant hand. No intervention was performed on the other hand. Cooling was performed with a frozen glove and compression was applied by 2 surgical gloves (1 size smaller than the tight-fitting size) 30 minutes before, after, and during taxane administration.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary end point was the efficacy to prevent grade 2 or higher sensory CIPN evaluated by Common Terminology Criteria for Adverse Events, version 5.0. Further CIPN assessment included the clinical version of the Total Neuropathy Score and QLQ CIPN20. CIPN rates were compared between intervention groups. Nail toxic effects, quality of life, CIPN-associated dose reductions, treatment discontinuations, and risk factors were evaluated. Follow-up examinations were performed 1 week, 1 month, and 6 to 8 months after the last taxane dose.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 122 female patients with primary breast cancer (mean [SD] age, 50 [12] years) were randomized to either cooling or compression of the dominant hand. Twenty-one individuals withdrew from the study, so 101 patients were included in the final analysis (n\u2009=\u200952 and n\u2009=\u200949 for cooling and compression, respectively). Both interventions significantly reduced the incidence of grade 2 or higher CIPN (cooling: 15 participants experiencing high-grade CIPN in the cooling arm [29%] vs 26 in the control arm [50%]; P<\/jats:italic>\u2009=\u2009.002; effect size, 21.15% [95% CI, 5.98%-35.55%]; compression: 12 participants experiencing CIPN in the intervention arm [24%] vs 19 in the control arm [38%]; P<\/jats:italic>\u2009=\u2009.008; effect size, 14.29% [95% CI, 2.02%-27.24%]). CIPN was the main reason for treatment discontinuations in 16 of 24 participants (67%). The predominant risk factors were the cumulative taxane dosage and the neurotoxic agent. Participants experiencing grade 2 or higher CIPN showed a reduced global health status during and 6 to 8 months after taxane therapy.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this randomized clinical trial, cooling and compression were highly effective and significantly reduced the risk of high-grade CIPN.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT06541769<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.0001","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T16:34:57Z","timestamp":1741278897000},"page":"408","source":"Crossref","is-referenced-by-count":44,"title":["Efficacy of Hand Cooling and Compression in Preventing Taxane-Induced Neuropathy"],"prefix":"10.1001","volume":"11","author":[{"given":"Laura L.","family":"Michel","sequence":"first","affiliation":[{"name":"National Center for Tumor Diseases, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Romar","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Feisst","sequence":"additional","affiliation":[{"name":"Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hamberger","sequence":"additional","affiliation":[{"name":"Asklepios Fachkliniken, Munich-Gauting, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Priester","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Kurre","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Klein","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany"},{"name":"Working Group Exercise Oncology, Division of Medical Oncology, National Center for Tumor Diseases (NCT) and University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Schink\u00f6the","sequence":"additional","affiliation":[{"name":"CANKADO GmbH, Ottobrunn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Weiler","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Smetanay","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany"},{"name":"Department of Obstetrics and Gynecology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Fremd","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Heublein","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany"},{"name":"Department of Obstetrics and Gynecology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Thewes","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael O.","family":"Breckwoldt","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"J\u00e4ger","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bendszus","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Marm\u00e9","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"coi250001r1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022.","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"coi250001r2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3322\/caac.21754","article-title":"Breast cancer statistics, 2022.","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"10286","key":"coi250001r3","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer.","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"coi250001r4","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"issue":"10","key":"coi250001r5","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","article-title":"Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up.","volume":"31","author":"Jordan","year":"2020","journal-title":"Ann Oncol"},{"issue":"28","key":"coi250001r6","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update.","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi250001r7","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.jpainsymman.2013.07.014","article-title":"Supportive cryotherapy: a review from head to toe.","volume":"47","author":"Kadakia","year":"2014","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"coi250001r8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-018-4983-8","article-title":"COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer.","volume":"173","author":"Smetanay","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"coi250001r9","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1007\/s00520-019-05217-x","article-title":"Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines.","volume":"28","author":"Correa","year":"2020","journal-title":"Support Care Cancer"},{"issue":"3","key":"coi250001r10","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/1097-0142(19940801)74:3<945::AID-CNCR2820740324>3.0.CO;2-C","article-title":"Inhibition of 5-fluorouracil-induced ocular irritation by ocular ice packs.","volume":"74","author":"Loprinzi","year":"1994","journal-title":"Cancer"},{"issue":"19","key":"coi250001r11","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1200\/JCO.2005.15.651","article-title":"Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand.","volume":"23","author":"Scott\u00e9","year":"2005","journal-title":"J Clin Oncol"},{"key":"coi250001r12","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3389\/fonc.2016.00274","article-title":"Limb hypothermia for preventing paclitaxel-induced peripheral neuropathy in breast cancer patients: a pilot study.","volume":"6","author":"Sundar","year":"2017","journal-title":"Front Oncol"},{"issue":"10","key":"coi250001r13","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1007\/s00520-018-4199-9","article-title":"Cold therapy to prevent paclitaxel-induced peripheral neuropathy.","volume":"26","author":"Griffiths","year":"2018","journal-title":"Support Care Cancer"},{"key":"coi250001r14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40780-016-0067-2","article-title":"The effectiveness of regional cooling for paclitaxel-induced peripheral neuropathy.","volume":"2","author":"Sato","year":"2016","journal-title":"J Pharm Health Care Sci"},{"issue":"2","key":"coi250001r15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jnci\/djx178","article-title":"Effects of cryotherapy on objective and subjective symptoms of paclitaxel-induced neuropathy: prospective self-controlled trial.","volume":"110","author":"Hanai","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"coi250001r16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.breast.2019.09.011","article-title":"Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial.","volume":"48","author":"Ruddy","year":"2019","journal-title":"Breast"},{"issue":"1","key":"coi250001r17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10549-016-3977-7","article-title":"Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group.","volume":"160","author":"Tsuyuki","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"coi250001r18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.breast.2019.06.008","article-title":"Effectiveness and safety of surgical glove compression therapy as a prophylactic method against nanoparticle albumin-bound-paclitaxel-induced peripheral neuropathy.","volume":"47","author":"Tsuyuki","year":"2019","journal-title":"Breast"},{"issue":"1","key":"coi250001r19","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1186\/s12885-021-08240-6","article-title":"Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial.","volume":"21","author":"Kotani","year":"2021","journal-title":"BMC Cancer"},{"issue":"8","key":"coi250001r20","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20.","volume":"41","author":"Postma","year":"2005","journal-title":"Eur J Cancer"},{"issue":"8","key":"coi250001r21","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1212\/WNL.53.8.1660","article-title":"Total Neuropathy Score: validation and reliability study.","volume":"53","author":"Cornblath","year":"1999","journal-title":"Neurology"},{"issue":"9","key":"coi250001r22","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1212\/01.WNL.0000092015.03923.19","article-title":"Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale.","volume":"61","author":"Cavaletti","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"coi250001r23","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1529-8027.2007.00141.x","article-title":"The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale.","volume":"12","author":"Cavaletti","year":"2007","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"coi250001r24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"coi250001r26","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1007\/s00520-019-04695-3","article-title":"Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors.","volume":"27","author":"Wong","year":"2019","journal-title":"Support Care Cancer"},{"issue":"4","key":"coi250001r27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpain.2017.02.281","article-title":"Characteristics of chemotherapy induced neuropathy (CIN) in cancer survivors who received taxol.","volume":"18","author":"Kober","year":"2017","journal-title":"J Pain"},{"issue":"6","key":"coi250001r28","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jpainsymman.2014.11.300","article-title":"Neuropathic symptoms and their risk factors in medical oncology outpatients with colorectal vs. breast, lung, or prostate cancer: results from a prospective multicenter study.","volume":"49","author":"Lewis","year":"2015","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"coi250001r29","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s00520-012-1667-5","article-title":"Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV.","volume":"21","author":"Vincenzi","year":"2013","journal-title":"Support Care Cancer"},{"issue":"6","key":"coi250001r30","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1312","article-title":"Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.","volume":"9","author":"Molassiotis","year":"2019","journal-title":"Brain Behav"},{"issue":"2","key":"coi250001r31","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ygyno.2018.12.002","article-title":"A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer.","volume":"152","author":"Bulls","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"2","key":"coi250001r32","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mds329","article-title":"The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.","volume":"24","author":"Cavaletti","year":"2013","journal-title":"Ann Oncol"},{"issue":"9","key":"coi250001r33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1212\/WNL.0000000000006083","article-title":"Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations.","volume":"91","author":"Gewandter","year":"2018","journal-title":"Neurology"},{"key":"coi250001r25","unstructured":"Cankado. Accessed January 31, 2025. http:\/\/www.cankado.com"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2830876\/jamaoncology_michel_2025_oi_250001_1744202984.98631.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T15:01:38Z","timestamp":1744902098000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2830876"}},"subtitle":["The POLAR Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.0001","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}